Chief executive officer Pascal Soriot also described the data from the AstraZeneca lung cancer drug trial as statistically positive.
The drugmaker’s shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called Tropion-Lung01 testing an experimental precision drug called datopotamab deruxtecan. Speaking to media today after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: staronline - 🏆 4. / 75 続きを読む »